Known active infections
Patients with clinically significant active infections
No active serious infections or other conditions precluding chemotherapy
Active serious infections not controlled by antibiotics
Must have no ongoing active, uncontrolled infections (afebrile for > 48 hours off antibiotics)
Any evidence of serious active infections; any infections being treated must complete antibiotic therapy at least 7 days before planned first dose.
Patient with active, uncontrolled infections (patients must be afebrile for > 48 hours off antibiotics).
Active infections
Patients with active infections. The principal investigator (PI) is the final arbiter of the eligibility;
Infections such as pneumonia or wound infections that would preclude protocol therapy.
Other active infections aside from hepatitis
FOR ALL PHASES (Ib AND II): Uncontrolled infection; active, clinically serious infections (> CTCAE grade 2)
No active infections
Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
Active infections within 48 hours of study entry
Evidence of active infections =< 7 days prior to initiation of study drug therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry)
Known active infections
CELL PROCUREMENT: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-respiratory syncytial virus (RSV), isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded
LYMPHODEPLETION: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-RSV, isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excluded
Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
Active clinically serious infections (> CTCAE grade 2)
Active known clinically serious infections
Evidence of active infections
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Evidence of active infections
Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved
Have active, acute, or chronic clinically significant infections.
Active Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections.
Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved
Recent or ongoing serious infections within 2 weeks
Active serious infections not controlled by antibiotics
Evidence of active infections
Active serious infections not controlled by antibiotics
Known infections:
Active clinically serious infections (? CTCAE v4.03 Grade 2).
Active infections
Active infections or oral temperature > 38.2º Celsius (C) within 48 hours of study entry
They have active infections such as hepatitis or fungal infections.
Active, unresolved infections
required parenteral antimicrobial therapy for active, intercurrent infections
Active clinically serious infections (> grade 2)
Active clinically serious infections > CTCAE Grade 2
Infections such as pneumonia or wound infections that would preclude protocol therapy
Active clinically serious infections
Any evidence of serious active infections
Patients must not have any active infections
Active serious infections not controlled by antibiotics
Active hepatitis or other active infections
Patients with active clinical infections
Active infections not responding to therapy; all efforts should be made to clear the infection prior to enrollment
Known active infections
c. Active or failed to control serious infections (CTCAE version 4.03 > grade 2 infections)
Known active infections
Active clinically serious infections (i.e. patients currently taking antibiotics)( Grade 2 NCI-CTC Version 3.0)
Any evidence of serious active infections.
DONOR: No active or chronic infections
8. Any evidence of serious active infections.
Patients with active infections, including HIV, will be excluded
Any evidence of serious active infections
Infections
Active clinically serious infections of > Grade 2 and/or active infections that require treatment with systemic agent
Patients with important infections requiring antibiotics are INELIGIBLE, but patients who acquire minor infections while on the study may remain on the study
Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
Active clinically serious infections of > Grade 2
Patients with any active hepatitis infections.
Patients must have no evidence of active infections at the time of transplantation
Patient with active infections
Treatment may be given to eligible patients with a single or multiple infections; patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enroll
active infections of the oral cavity
Active infection (except mild upper respiratory infections)
Patients with clinically significant active infections
Patients with known active treatment for hepatitis B and C infections
Active serious infections not controlled by antibiotics
Patients should not have active infections or concurrent neoplastic disease except for skin cancer
Active acute infection (i.e. currently treated with antibiotics); patients with chronic infections such as hepatitis B or C, mycobacterium avium or similar infections will be eligible provided they meet all other eligibility criteria
Patients with known active treatment for hepatitis B and C infections
Clinically active hepatitis A, B, or C infections
Active infections of oral cavity
Patients with active treatment for active hepatitis B and C infections
Patients with active infections.